- Conditions
- Generalized Myasthenia Gravis, gMG
- Interventions
- Ravulizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 85
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myasthenia Gravis, Myasthenia Gravis, Generalized
- Interventions
- No intervention
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Myasthaenia Gravis, Myasthenia, Myasthenia Gravis Associated with Thymoma, Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, Myasthenia Gravis Generalised, Myasthenia Gravis with Exacerbation (Disorder), Myasthenia Gravis, Adult Form, Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular, Myasthenia Gravis, Thymectomy, Myasthenia Gravis, Myasthenia Gravis, MuSK
- Interventions
- Not listed
- Lead sponsor
- Myasthenia Gravis Foundation of America
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2029
- U.S. locations
- 1
- States / cities
- Westborough, Massachusetts
- Conditions
- Generalized Myasthenia Gravis, gMG
- Interventions
- Efgartigimod IV or Efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Charlotte, North Carolina • Charlottesville, Virginia
- Conditions
- Myasthenia Gravis
- Interventions
- ARGX-113, Placebo
- Biological · Drug
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Irvine, California • Los Angeles, California • Tampa, Florida + 3 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Efgartigimod IV
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Chapel Hill, North Carolina • Charlottesville, Virginia
- Conditions
- Myasthenia Gravis
- Interventions
- Nipocalimab, Placebo, Nipocalimab SC-LIV
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 24
- States / cities
- Paradise Valley, Arizona • Scottsdale, Arizona • Los Angeles, California + 21 more
- Conditions
- Multiple Sclerosis, Myasthenia Gravis
- Interventions
- CC-97540, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Aritinercept, Placebo
- Drug · Other
- Lead sponsor
- Aurinia Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 11
- States / cities
- Pasadena, California • Altamonte Springs, Florida • Boca Raton, Florida + 7 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Ravulizumab, Placebo
- Biological · Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fresno, California + 29 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Charlotte, North Carolina • Denton, Texas • Charlottesville, Virginia
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- zilucoplan (RA101495)
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Rancho Mirage, California + 9 more
- Conditions
- Generalized Myasthenia Gravis (gMG)
- Interventions
- CABA-201
- Biological
- Lead sponsor
- Cabaletta Bio
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 17
- States / cities
- Orange, California • Sacramento, California • San Francisco, California + 12 more
- Conditions
- Myasthenia Gravis (MG), Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular, Myasthenia Gravis Crisis, Myasthenia Gravis Associated With Thymoma, Myasthenia Gravis Exacerbations, Myasthenia Gravis Generalised, Myasthenia Gravis Generalized, Myasthenia Gravis, Thymectomy, Myasthenia Gravis, Myasthenia Gravis, MuSK, AChR Myasthenia Gravis, AChR-Ab Seropositive Generalized Myasthenia Gravis, MG, MG - Myasthenia Gravis
- Interventions
- Not listed
- Lead sponsor
- Autoimmune Neurology Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 1
- States / cities
- Framingham, Massachusetts
- Conditions
- Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness
- Interventions
- anito-cel, Standard Lymphodepletion regimen
- Biological · Drug
- Lead sponsor
- Arcellx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 10 more
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
- Interventions
- Specimen sample
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Generalized Myasthenia Gravis (gMG)
- Interventions
- Zilucoplan®
- Drug
- Lead sponsor
- Miriam Freimer
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Kansas City, Kansas • Columbus, Ohio
- Conditions
- Myasthaenia Gravis
- Interventions
- Belimumab, Placebo
- Biological · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 12 more
- Conditions
- Myasthenia Gravis
- Interventions
- IM-101 Part A, Placebo Part A, IM-101 Part B, Placebo Part B
- Drug
- Lead sponsor
- ImmunAbs Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- Altamonte Springs, Florida • Boca Raton, Florida • Naples, Florida + 4 more
- Conditions
- Myasthenia Gravis
- Interventions
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Drug
- Lead sponsor
- Muscular Dystrophy Association
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Zilucoplan
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Tampa, Florida • Columbia, Missouri + 4 more
- Conditions
- Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
- Interventions
- Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- Carlsbad, California • Miami, Florida • Tampa, Florida + 11 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Zilucoplan
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Flower Mound, Texas